Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Intron-A for hepatitis B saves $6,600 per patient in medical costs, AIM study projects.

Executive Summary

SCHERING's INTRON A SAVES $6,600 PER HEPATITIS B PATIENT v. standard care in lifetime medical costs, according to a cost-effectiveness study of Schering's alpha interferon product published May 1 in the Annals of Internal Medicine. The authors, John Wong, MD, et al., from the New England Medical Center and Tufts University School of Medicine, conducted a meta-analysis of nine randomized controlled clinical trials of Intron A for hepatitis B, projected outcomes based on serological markers used in the trials and modeled costs for standard care versus Intron A therapy. The authors conclude that lifetime costs of standard care would be $60,200 per patient versus $53,600 for Intron A treatment.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel